Successful partnerships

Villamañán de Santiago, Lucía|||0000-0002-6702-2103; Martínez-Escardó, Laura|||0000-0003-2979-4804; Arús i Caraltó, Carles|||0000-0003-2510-2671; Yuste, Victor José|||0000-0001-5322-9261; Candiota Silveira, Ana Paula|||0000-0002-1523-6505

Successful partnerships

The relevance of the cancer immune cycle in therapy response implies that successful treatment may trigger the exposure or the release of immunogenic signals. Previous results with the preclinical GL261 glioblastoma (GB) showed that combination treatment of temozolomide (TMZ) + CX-4945 (protein kina...

Descripción completa

Detalles Bibliográficos
Autores:	Villamañán de Santiago, Lucía\|\|\|0000-0002-6702-2103, Martínez-Escardó, Laura\|\|\|0000-0003-2979-4804, Arús i Caraltó, Carles\|\|\|0000-0003-2510-2671, Yuste, Victor José\|\|\|0000-0001-5322-9261, Candiota Silveira, Ana Paula\|\|\|0000-0002-1523-6505
Tipo de recurso:	artículo
Fecha de publicación:	2021
País:	España
Institución:	Universitat Autònoma de Barcelona
Repositorio:	Dipòsit Digital de Documents de la UAB
Idioma:	inglés
OAI Identifier:	oai:ddd.uab.cat:238349
Acceso en línea:	https://ddd.uab.cat/record/238349 https://dx.doi.org/urn:doi:10.3390/ijms22073453
Access Level:	acceso abierto
Palabra clave:	Preclinical glioblastoma Cancer immune cycle Immunogenic signals Calreticulin ATP Protein kinase CK2 Temozolomide

id	ES_aa07e33cd60f4a1bb6c1d8f9d70c78b2
oai_identifier_str	oai:ddd.uab.cat:238349
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Successful partnershipsexploring the potential of immunogenic signals triggered by TMZ, CX-4945 and combined treatment in GL261 glioblastoma cellsVillamañán de Santiago, Lucía\|\|\|0000-0002-6702-2103Martínez-Escardó, Laura\|\|\|0000-0003-2979-4804Arús i Caraltó, Carles\|\|\|0000-0003-2510-2671Yuste, Victor José\|\|\|0000-0001-5322-9261Candiota Silveira, Ana Paula\|\|\|0000-0002-1523-6505Preclinical glioblastomaCancer immune cycleImmunogenic signalsCalreticulinATPProtein kinase CK2TemozolomideThe relevance of the cancer immune cycle in therapy response implies that successful treatment may trigger the exposure or the release of immunogenic signals. Previous results with the preclinical GL261 glioblastoma (GB) showed that combination treatment of temozolomide (TMZ) + CX-4945 (protein kinase CK2 inhibitor) outperformed single treatments, provided an immune-friendly schedule was followed. Our purpose was to study possible immunogenic signals released in vitro by GB cells. Methods: GL261 GB cells were treated with TMZ and CX-4945 at different concentrations (25 µM-4 mM) and time frames (12-72 h). Cell viability was measured with Trypan Blue and propidium iodide. Calreticulin exposure was assessed with immunofluorescence, and ATP release was measured with bioluminescence. Results: TMZ showed cytostatic rather than cytotoxic effects, while CX-4945 showed remarkable cytotoxic effects already at low concentrations. Calreticulin exposure after 24 h was detected with TMZ treatment, as well as TMZ/CX-4945 low concentration combined treatment. ATP release was significantly higher with CX-4945, especially at high concentrations, as well as with TMZ/CX-4945. Conclusions: combined treatment may produce the simultaneous release of two potent immunogenic signals, which can explain the outperformance over single treatments in vivo. A word of caution may be raised since in vitro conditions are not able to mimic pharmacokinetics observed in vivo fully. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/238349https://dx.doi.org/urn:doi:10.3390/ijms22073453reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengEuropean Commission https://doi.org/10.13039/501100000780 777222Ministerio de Sanidad y Consumo CB06/01/0010Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2018/XARDI-00016open accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2383492026-06-06T12:50:31Z
dc.title.none.fl_str_mv	Successful partnerships exploring the potential of immunogenic signals triggered by TMZ, CX-4945 and combined treatment in GL261 glioblastoma cells
title	Successful partnerships
spellingShingle	Successful partnerships Villamañán de Santiago, Lucía\|\|\|0000-0002-6702-2103 Preclinical glioblastoma Cancer immune cycle Immunogenic signals Calreticulin ATP Protein kinase CK2 Temozolomide
title_short	Successful partnerships
title_full	Successful partnerships
title_fullStr	Successful partnerships
title_full_unstemmed	Successful partnerships
title_sort	Successful partnerships
dc.creator.none.fl_str_mv	Villamañán de Santiago, Lucía\|\|\|0000-0002-6702-2103 Martínez-Escardó, Laura\|\|\|0000-0003-2979-4804 Arús i Caraltó, Carles\|\|\|0000-0003-2510-2671 Yuste, Victor José\|\|\|0000-0001-5322-9261 Candiota Silveira, Ana Paula\|\|\|0000-0002-1523-6505
author	Villamañán de Santiago, Lucía\|\|\|0000-0002-6702-2103
author_facet	Villamañán de Santiago, Lucía\|\|\|0000-0002-6702-2103 Martínez-Escardó, Laura\|\|\|0000-0003-2979-4804 Arús i Caraltó, Carles\|\|\|0000-0003-2510-2671 Yuste, Victor José\|\|\|0000-0001-5322-9261 Candiota Silveira, Ana Paula\|\|\|0000-0002-1523-6505
author_role	author
author2	Martínez-Escardó, Laura\|\|\|0000-0003-2979-4804 Arús i Caraltó, Carles\|\|\|0000-0003-2510-2671 Yuste, Victor José\|\|\|0000-0001-5322-9261 Candiota Silveira, Ana Paula\|\|\|0000-0002-1523-6505
author2_role	author author author author
dc.subject.none.fl_str_mv	Preclinical glioblastoma Cancer immune cycle Immunogenic signals Calreticulin ATP Protein kinase CK2 Temozolomide
topic	Preclinical glioblastoma Cancer immune cycle Immunogenic signals Calreticulin ATP Protein kinase CK2 Temozolomide
description	The relevance of the cancer immune cycle in therapy response implies that successful treatment may trigger the exposure or the release of immunogenic signals. Previous results with the preclinical GL261 glioblastoma (GB) showed that combination treatment of temozolomide (TMZ) + CX-4945 (protein kinase CK2 inhibitor) outperformed single treatments, provided an immune-friendly schedule was followed. Our purpose was to study possible immunogenic signals released in vitro by GB cells. Methods: GL261 GB cells were treated with TMZ and CX-4945 at different concentrations (25 µM-4 mM) and time frames (12-72 h). Cell viability was measured with Trypan Blue and propidium iodide. Calreticulin exposure was assessed with immunofluorescence, and ATP release was measured with bioluminescence. Results: TMZ showed cytostatic rather than cytotoxic effects, while CX-4945 showed remarkable cytotoxic effects already at low concentrations. Calreticulin exposure after 24 h was detected with TMZ treatment, as well as TMZ/CX-4945 low concentration combined treatment. ATP release was significantly higher with CX-4945, especially at high concentrations, as well as with TMZ/CX-4945. Conclusions: combined treatment may produce the simultaneous release of two potent immunogenic signals, which can explain the outperformance over single treatments in vivo. A word of caution may be raised since in vitro conditions are not able to mimic pharmacokinetics observed in vivo fully.
publishDate	2021
dc.date.none.fl_str_mv	2 2021-01-01 2021 2021-01-01
dc.type.none.fl_str_mv	Article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://ddd.uab.cat/record/238349 https://dx.doi.org/urn:doi:10.3390/ijms22073453
url	https://ddd.uab.cat/record/238349 https://dx.doi.org/urn:doi:10.3390/ijms22073453
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.relation.none.fl_str_mv	European Commission https://doi.org/10.13039/501100000780 777222 Ministerio de Sanidad y Consumo CB06/01/0010 Agència de Gestió d'Ajuts Universitaris i de Recerca https://doi.org/10.13039/501100003030 2018/XARDI-00016
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.source.none.fl_str_mv	reponame:Dipòsit Digital de Documents de la UAB instname:Universitat Autònoma de Barcelona
instname_str	Universitat Autònoma de Barcelona
reponame_str	Dipòsit Digital de Documents de la UAB
collection	Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869416109152665600
score	15,300719

Successful partnerships

Similares en LA Referencia